Meeting
2023 ASCO Quality Care Symposium
Endocrine therapy initiation among women diagnosed with ductal carcinoma in situ breast cancer from 2001-2016.
Authors
Erin Aiello Bowles
Kaiser Permanente Washington Health Research Institute, Seattle, WA
Erin Aiello Bowles, Cody Ramin, Heather S. Feigelson, Jennifer C Gander, Lene H. S. Veiga, Clara Bodelon, Rochelle E. Curtis, Carolyn Brandt, Jacqueline B Vo, Amy Berrington de González, Gretchen Gierach
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Quality, Safety, and Implementation Science,Cost, Value, and Policy,Patient Experience,Survivorship
Sub Track
Chronic Anticancer Therapy
Citation
JCO Oncol Pract 19, 2023 (suppl 11; abstr 487)
DOI
10.1200/OP.2023.19.11_suppl.487
Abstract #
487
Poster Bd #
L13
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Disparities in surveillance imaging after breast conserving surgery for primary DCIS.
First Author: Danalyn Byng
Poster
2020 ASCO Virtual Scientific Program
A novel biosignature to assess residual risk in ductal carcinoma in situ (DCIS) patients after standard treatment.
First Author: Troy Bremer
Poster
2018 ASCO Annual Meeting
Treatment and outcomes in older women with DCIS: SEER-Medicare 2007-2013.
First Author: Mary Chen Schroeder
Poster
2024 ASCO Annual Meeting
Identification of patients with DCIS with low-risk clinicopathology who benefit from radiation therapy with and without endocrine therapy after breast-conserving surgery assessed with the 7-gene biosignature.
First Author: Pat W. Whitworth